Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zapnometinib Phase I Dose Escalation in Healthy Subjects
NCT05555823Phase 1Completed
- Sponsor
- Atriva Therapeutics
- Start
- Jun 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in influenza and coronavirus disease 2019 (COVID-19) comparing ATR-002 with Placebo (2 arms). Primary endpoint: Number of participants with TEAEs and SAEs, with abnormal ECG readings, abnormal vital signs, and abnormal laboratory parameters. Started Jun 2022; status: completed.
02
Drugs
Zapnometinib
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05555823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555823.